Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 382M |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Renal |
| Current Generation (* indicates number of generations grown in Castrate host) |
11 |
| Average PDX Generation Time (days +/- SEM) | 41 ± 4 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 382M |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | N |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 382M | TP53 | -1.403 | 0.757 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 382M | SUFU | -0.967 | 1.023 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 382M | RB1 | -0.923 | 1.055 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 382M | PTEN | -0.967 | 1.023 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 382M | PIK3CB | 0.971 | 3.921 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 382M | PIK3CA | 0.596 | 3.023 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 382M | MYC | 1.164 | 4.482 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 382M | KMT2C | 0.538 | 2.903 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 382M | KMT2C | -0.949 | 1.036 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 382M | FANCA | -1.427 | 0.744 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 382M | CTNNB1 | 0.644 | 3.125 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 382M | CHD1 | -14.854 | 6.760e-05 | Homdel | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 382M | CDKN1B | -0.861 | 1.101 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 382M | AR | -5.064 | 0.030 | GSR | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
Clinical Information
| Sample Number | 382M |
|---|---|
| Sample Site | Liver |
| Sample source | Biopsy |
| Pathology Tumour Diagnosis | None |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, docetaxel, cabazitaxel, abiraterone |
Patient Information
| Patient Number | 175/382 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | NA |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 382M |
| Patient Age (binned in 5 year age groups) | 70-74 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 382M | BTK | 181 | 0.99 | Missense variant | '12/19 | . | 26.9 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 382M | PTEN | 227 | 0.98 | Missense variant | '5/9 | . | 27.2 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 382M | PTCH1 | 393 | 0.51 | Missense variant | '9/24 | 0.0007269 | 23.6 | Conflicting interpretations of pathogenicity | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 382M | SETD2 | 404 | 0.48 | Missense variant | '3/21 | 0.0005031 | 29.4 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 382M | LRP2 | 351 | 0.47 | Missense variant | '22/79 | . | 0.437 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 382M | SPOP | 370 | 0.46 | Missense variant | '7/12 | 4.07E-06 | 23.7 | Conflicting interpretations of pathogenicity | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 382M | GRIN2A | 1018 | 0.35 | Missense variant | '13/14 | . | 24.9 | Uncertain significance | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 382M | EPHA5 | 359 | 0.32 | Frameshift variant | '1/18 | . | . | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 382M | MYCN | 234 | 0.31 | Inframe deletion | '2/3 | . | . | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 382M | AR | 381 | 0.27 | GSR | '1/8 | . | . | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
No information in Drug dosing Table